文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

中和单克隆抗体预防COVID-19门诊患者住院和死亡的真实世界证据

Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
PubMed 文献 · Chest · 2022-10-28
一句话结论观察性队列显示,门诊COVID-19患者接受中和单克隆抗体与28天住院(4.0% vs 7.7%,调整OR 0.48)和死亡(0.1% vs 0.9%,调整OR 0.11)降低相关。

这项观察性队列研究纳入2020年11月至2021年10月全州医疗系统电子健康记录中非住院成人SARS-CoV-2感染者,采用倾向性匹配,将2675例接受中和单克隆抗体治疗的患者与6677例未接受者匹配。结果显示,治疗组28天全因住院率4.0% vs 7.7%(调整OR 0.48;95%CI 0.38-0.60),全因死亡率0.1% vs 0.9%(调整OR 0.11;95%CI 0.03-0.29),差异持续至第90天;住院患者住院时间5.8 vs 8.5天,机械通气风险4.6% vs 16.6%。Delta变异株阶段预防住院的调整OR为0.35(95%CI 0.25-0.50),各亚组结果相似。作者认为真实世界数据应指导实践和政策决策,包括稀缺资源分配。

要点

  • 接受mAb治疗的门诊COVID-19患者28天全因住院率4.0% vs 未治疗者7.7%,调整OR 0.48(95%CI 0.38-0.60)。
  • 28天全因死亡率0.1% vs 0.9%,调整OR 0.11(95%CI 0.03-0.29),差异持续至第90天。
  • 住院患者中,mAb治疗者住院时间5.8 vs 8.5天,机械通气风险4.6% vs 16.6%。
  • Delta变异株阶段预防住院调整OR 0.35(95%CI 0.25-0.50),各亚组结果相似。
  • 预防住院NNT在基线住院风险更高的亚组更低:多种合并症NNT=17、未完全接种NNT=24,无合并症NNT=88、完全接种NNT=81。

适用人群与场景

  • 2020年11月至2021年10月,来自全州医疗系统电子健康记录的非住院成人SARS-CoV-2感染者,结合州级疫苗和死亡数据。

研究设计与关键结果

  • 研究类型为观察性队列研究,纳入36077例SARS-CoV-2感染患者,其中2675例接受mAb治疗者经倾向性匹配至6677例未接受mAb治疗者。
  • 主要终点28天全因住院:mAb治疗组4.0% vs 未治疗组7.7%,调整OR 0.48(95%CI 0.38-0.60)。
  • 次要终点28天全因死亡:mAb治疗组0.1% vs 未治疗组0.9%,调整OR 0.11(95%CI 0.03-0.29);差异持续至第90天。
  • 住院患者中,mAb治疗组住院时间5.8天 vs 未治疗组8.5天,机械通气风险4.6% vs 16.6%。
  • Delta变异株阶段预防住院调整OR 0.35(95%CI 0.25-0.50),各亚组结果相似。
  • 预防住院NNT:多种合并症亚组NNT=17、未完全接种亚组NNT=24,无合并症亚组NNT=88、完全接种亚组NNT=81。

证据类型、等级与局限

  • 证据类型:观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为真实世界数据研究应被用于指导实践和政策决策,包括稀缺资源的分配。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Neutralizing monoclonal antibodies (mAbs) were authorized for the treatment of COVID-19 outpatients based on clinical trials completed early in the pandemic, which were underpowered for mortality and subgroup analyses. Real-world data studies are promising for further assessing rapidly deployed therapeutics.

RESEARCH QUESTION: Did mAb treatment prevent progression to severe disease and death across pandemic phases and based on risk factors, including prior vaccination status?

STUDY DESIGN AND METHODS: This observational cohort study included nonhospitalized adult patients with SARS-CoV-2 infection from November 2020 to October 2021 using electronic health records from a statewide health system plus state-level vaccine and mortality data. Using propensity matching, we selected approximately 2.5 patients not receiving mAbs for each patient who received mAb treatment under emergency use authorization. The primary outcome was 28-day hospitalization; secondary outcomes included mortality and hospitalization severity.

RESULTS: Of 36,077 patients with SARS-CoV-2 infection, 2,675 receiving mAbs were matched to 6,677 patients not receiving mAbs. Compared with mAb-untreated patients, mAb-treated patients had lower all-cause hospitalization (4.0% vs 7.7%; adjusted OR, 0.48; 95% CI, 0.38-0.60) and all-cause mortality (0.1% vs 0.9%; adjusted OR, 0.11; 95% CI, 0.03-0.29) to day 28; differences persisted to day 90. Among hospitalized patients, mAb-treated patients had shorter hospital length of stay (5.8 vs 8.5 days) and lower risk of mechanical ventilation (4.6% vs 16.6%). Results were similar for preventing hospitalizations during the Delta variant phase (adjusted OR, 0.35; 95% CI, 0.25-0.50) and across subgroups. Number-needed-to-treat (NNT) to prevent hospitalization was lower for subgroups with higher baseline risk of hospitalization; for example, multiple comorbidities (NNT = 17) and not fully vaccinated (NNT = 24) vs no comorbidities (NNT = 88) and fully vaccinated (NNT = 81).

INTERPRETATION: Real-world data revealed a strong association between receipt of mAbs and reduced hospitalization and deaths among COVID-19 outpatients across pandemic phases. Real-world data studies should be used to guide practice and policy decisions, including allocation of scarce resources.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Wynia MK, Beaty LE, Bennett TD, et al. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Chest. 2022. PMID: 36441040. doi:10.1016/j.chest.2022.10.020

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。